In isolated islets, the hydrolysis of membrane phosphoinositides (PI) participates in the transduction of both extracellular and intracellular signals into an effective insulin secretory response. A wide variety of potential second-messenger molecules are generated during the phospholipase C-mediated cleavage of these strategically situated membrane phospholipids. Several distinct but interrelated issues are addressed in this perspective. These include 1) methodological approaches utilized to assess PI turnover, 2) the synergistic relationship between PI-derived second messengers and cAMP, 3) the contribution of changing PI turnover rates to the biphasic pattern of insulin output induced by 20 mM glucose, and 4) the role played by PI turnover in the phenomenon of "memory" displayed by islets after prior stimulation with various agonists. The concept that events unique to PI turnover contribute to beta-cell activation is well founded. Because of uncertainty regarding the exact nature of all PI-derived messengers, however, it is not yet possible to mold the available information into a comprehensive theory of beta-cell activation. Future studies will have to address various important unresolved issues.

Extant data suggest that a Ca2+- and phospholipid-dependent protein kinase C (PKC) exists (as a single enzyme or possibly a family of related enzymes) in rodent beta-cells. PKC activators probably induce secretion primarily through phosphorylation of key proteins, thereby sensitizing the exocytotic apparatus to Ca2+. PKC can be activated by several pharmacologic probes and by endogenous diacylglycerol (and possibly arachidonic acid) released by nutrient-activated phospholipases. Several nonspecific pharmacologic agents inhibit both PKC and physiologic insulin release. However, when a more specific inhibitor of PKC, H7 [1-(5-isoquinolinylsulfonyl)-2-methylpiperazine], was studied, it did not reduce glucose-induced insulin secretion. Moreover, prolonged preexposure of islets to a phorbol ester (believed to induce selective depletion of PKC) also failed to substantially reduce the subsequent secretory response to glucose. Thus, indisputable evidence for an obligatory physiological role of PKC in the islet is still missing, and the enzyme's status as a critical coupling signal should be viewed as putative only.

Evidence for an abnormal myocardial cell function in diabetes mellitus, influenced by acute metabolic changes, has appeared within recent years. Few but interesting clinical studies focus on this aspect of diabetic cardiopathy, and experimental studies have delivered possible explanations at the cellular level. These are concerned with the intracellular calcium homeostasis and transsarcolemmal receptor signaling. Because these changes are reversible by short-term insulin treatment, a new aspect for the study of diabetic heart disease has appeared.

Recent studies indicate that insulin directly regulates the acinar pancreas. Morphologic and hemodynamic studies indicate the presence of a portal system that conveys islet blood to acinar cells. Studies both in humans with diabetes mellitus and in animals given beta cell toxins indicate that insulin is necessary for normal acinar cell function. Studies in the perfused rat pancreas indicate that endogenous insulin potentiates zymogen release. Isolated rat and mouse acini have insulin receptors, and in these cells, after binding to its receptors, insulin regulates a number of functions including: sugar transport, protein synthesis, and the number of cholecystokinin receptors. These in vivo and in vitro studies suggest, therefore, that there is an insulin-pancreatic acinar axis that plays a major role in pancreatic function.

Most studies of gestational diabetes mellitus (GDM) have reported a marked reduction in perinatal mortality with appropriate dietary regimens and good medical and obstetrical surveillance. Nevertheless, fetal morbidity, including macrosomia, has remained high and appears to be linked to factors other than plasma glucose control. In a review of six investigations in which insulin therapy was combined with an appropriate diet, the incidence of fetal macrosomia was reduced in five studies as compared with diet-only treatments. Again, the improvement did not always correlate with altered plasma glucose profiles. Other studies suggest that maternal plasma substrate disturbances other than glucose may contribute to the development of fetal macrosomia. To what extent insulin administration reduces morbidity by containing circulating maternal fuels, such as lipids and amino acids, in a more normal range remains to be determined. Moreover, the role of diet, maternal obesity, and weight gain during pregnancy adds to the complexity of factors influencing obstetrical outcome in gestational diabetes. Until the relative importance of all of these variables is adequately assessed, criteria for selection of women with pregnancy-onset diabetes for insulin therapy are most likely to be based on fasting and postprandial plasma glucose concentrations.

Treatment with conventional insulin preparations results in appreciable insulin antibody formation in nearly all subjects. High titers of insulin antibodies are undesirable. They might induce insulin allergy and insulin resistance, and they influence metabolic regulation. Also, lipoatrophy is related to the immunogenicity of insulin preparations. Insulin antibodies are transferred from insulin-treated diabetic mothers to the fetus and contribute to the increase of free plasma insulin in the fetus, thus influencing the development of macrosomia and neonatal hypoglycemia. Therefore, the risk of insulin antibody formation should be reduced. This is possible by using purified, nonbeef insulin preparations. The risk of insulin allergy, insulin resistance, lipoatrophy, and prolonged hypoglycemia in mother and child is reduced by treating pregnant diabetic subjects with purified pork or human insulin preparations. The reduction of insulin requirement that accompanies the change from conventional insulin to purified nonbeef insulin treatment will compensate to some extent for the higher costs of new insulins.

The prevalence of diabetes and of gestational diabetes varies considerably between countries and within countries. There are also major national and international differences in the important end points of fetal or neonatal death and congenital fetal abnormality. These differences relate to multiple factors, of which diabetes or gestational diabetes represents only a part of the total pathologic effect. There is also international disagreement on the most appropriate diagnostic criteria for gestational diabetes. The main uncertainty is whether to adopt the World Health Organization figures, e.g., venous plasma glucose 2 h after 75 g glucose greater than or equal to 140 mg/dl (8.0 mmol/L) as gestational impaired glucose tolerance, and greater than or equal to 200 mg/dl (11.0 mmol/L) as gestational diabetes, or to use the Boston figures, e.g., venous plasma glucose 2 h after 100 g glucose greater than or equal to 165 mg/dl (9.5 mmol/L) as gestational diabetes. It is hoped that standards for pathologic hyperglycemia in pregnancy can be agreed on for use in all countries for all populations.

In pregnancy, several physiologic changes take place, the sum of which tends to reset the glucose homeostasis in the direction of diabetes. About 1-2% of all pregnant women develop an abnormal glucose tolerance in pregnancy, but most often glucose tolerance returns to normal postpartum. This condition is called gestational diabetes mellitus (GDM). The possibility that glucose tolerance deteriorates in pregnancy because of diabetes-like changes in the secretory function of the endocrine pancreas has been investigated in healthy controls and in normal-weight gestational diabetic subjects. The insulin responses to oral glucose and mixed meals are equally large in these two groups, but the insulin response per unit of glycemic stimulus is significantly lower in the gestational diabetic subjects than in the controls. Diabetes-like changes in glucagon secretion are not observed in either group. Insulin degradation is unaffected by human pregnancy and the proinsulin share of the total plasma insulin immunoreactivity does not increase in pregnancy. Insulin receptor binding to monocytes from normal pregnant women is increased in midpregnancy but is significantly decreased in late pregnancy. No difference in insulin binding (at tracer insulin concentration) to monocytes from healthy pregnant controls and gestational diabetic subjects is found. The insulin concentration necessary to reduce tracer insulin binding by 50% (ID50) is lower in the gestational diabetic subjects diagnosed in late pregnancy than in the pregnant controls. Together, these findings indicate that the number of insulin receptors on monocytes is decreased in GDM at this stage of pregnancy.(ABSTRACT TRUNCATED AT 250 WORDS)

This article reviews the effects of pregnancy on carbohydrate metabolism and insulin production in the normal rat and discusses some animal models of potential value for the study of gestational diabetes mellitus (GDM). Against the background of current clinical and laboratory experiences it is suggested that GDM reflects a deficiency in islet B-cell proliferation in response to the increased insulin requirement during pregnancy. Although this hypothesis lends itself for testing in animal experiments, a suitable animal model for GDM needs to be described.

The large and variable hepatic extraction of insulin is a major obstacle to our ability to quantitate insulin secretion accurately in human subjects. The evidence that C-peptide is secreted from the beta cell in equimolar concentration with insulin, but not extracted by the liver to any significant degree, has provided a firm scientific basis for the use of peripheral C-peptide concentrations as a semiquantitative marker of beta cell secretory activity in a variety of clinical situations. Thus, plasma C-peptide has proved to be extremely valuable in the study of the natural history of type 1 diabetes, to monitor insulin secretion in patients with insulin antibodies, and as an adjunct in the investigation of patients with hypoglycemic disorders. The use of the peripheral C-peptide concentration to accurately quantitate the rate of insulin secretion is more controversial. This is mainly because understanding of the kinetics and metabolism of C-peptide under different conditions is incomplete. Unfortunately, sufficient quantities of human C-peptide are not available to allow the experimental validation of the mathematical formulae that have been proposed for the calculation of insulin secretion from peripheral C-peptide concentrations. Until it is possible to perform such experiments, the accuracy of studies that have derived insulin secretion rates from peripheral C-peptide levels will remain uncertain. The assumption that the peripheral C-peptide:insulin molar ratio can be used as a reflection of hepatic insulin extraction has not been experimentally validated. The marked difference in the plasma half-lives of insulin and C-peptide complicates the interpretation of changes in their ratios.(ABSTRACT TRUNCATED AT 250 WORDS)

In discussions of vascular complications of diabetes the fact that capillary basement membranes are, in general, thickened (CBMT) in poorly controlled diabetics is no longer at issue. However, three important questions concerning the pathophysiologic significance of CBMT remain unanswered: (1) How and why do capillary basement membranes thicken in diabetes? (2) What is the functional significance of capillary basement membrane changes in diabetes? (3) What is the nature of the relationship of CBMT to other forms of diabetic vascular disease; in particular, is CBMT observed in tissues amenable to needle biopsy, i.e., skeletal muscle, useful in identifying individuals at high risk for developing clinically significant retinopathy, nephropathy, or atherosclerotic vascular disease? In this survey, we will consider the nature of capillary basement membrane changes in diabetes and subsequently address the above questions.

Abnormalities of rheologic and hemostatic properties of blood are present in uncontrolled diabetics and play a role in the development of structural micro- and macroangiopathies. Red blood cell deformability is decreased in diabetics and shows negative correlation with fast hemoglobin and actual blood glucose levels. In uncontrolled insulin-dependent diabetics, normalization of plasma glucose by an insulin infusion improves red cell deformability in 2 h. Insulin infusion (0.2 U/kg/h) [the initial hyperglycemia being maintained (hyperglycemic clamp)] also improves red cell deformability. Deformability of normal erythrocytes is reduced by incubation in plasma from uncontrolled diabetics but is normal in plasma from diabetics controlled by a 24-h insulin infusion or in diabetic plasma with insulin added in vitro. Therefore, insulin appears to have a direct effect on erythrocyte deformability. Platelet aggregation measured in whole blood is raised in uncontrolled diabetics. Aggregation of normal platelets rises in the presence of "diabetic" red cells but not in the presence of red cells from the same patients controlled by 24-h treatment with insulin. The effect of insulin on platelet aggregation, therefore, seems to be at least partly mediated by erythrocytes.

Our longitudinal study of urinary albumin excretion rate in long-term insulin-dependent diabetics without proteinuria (negative albustix) suggests that early detection of patients at high and low risk of developing persistent proteinuria, i.e., diabetic nephropathy, is possible by using a sensitive method for albumin determination. Our prospective studies in young insulin-dependent diabetics with diabetic nephropathy show that the rate of decline in glomerular filtration rate (GFR) varies considerably, with a mean of 0.75 ml/min/mo and a range from 0.1 to 1.50 ml/min/mo, and that an increase in arterial blood pressure to a hypertensive level is an early feature; 43% of the patients had diastolic blood pressure greater than 100 mm Hg. Early and aggressive antihypertensive treatment reduces both albuminuria and the rate of decline in GFR in young patients with diabetic nephropathy.

Studies of the glomerular structure in diabetes mellitus have helped to elucidate the basis for some functional abnormalities. The decline in glomerular filtration occurring in many long-term diabetics is a functional disorder of great clinical importance. Quantitative structural studies of the glomeruli in diabetics at different stages of disease are necessary to learn about the development of structural changes leading to the end-stage kidney disease. Preliminary results of a study of glomeruli from long-term diabetics with clinical nephropathy are compared with those obtained in control subjects and in diabetics within the first 5 yr of disease. In the long-term diabetics the peripheral basement membrane thickness was doubled. On the average, mesangial regions occupied nearly 60% of the total tuft volume as compared with 33% in the early stages. A marked accumulation of basement membrane material in the mesengial regions had taken place so that 85% of the total basement membrane material of the tufts (i.e., peripheral basement membrane in the capillary walls plus mesangial basement membrane-like material) was localized within the mesangial regions. In the early stages equal amounts were found at these two different sites. The distribution of the lesions within the kidney is under investigation in a light microscopic study of autopsy material from long-term diabetics with varying degrees of glomerulopathy. The severity of the diabetic glomerulopathy was quantitated separately within the superficial and the deep cortical zones. The results showed that there was no tendency toward increased severity in the deep glomeruli.(ABSTRACT TRUNCATED AT 250 WORDS)